Design, Characterization and Anti-Tumor Activity of Adriamycin-Containing Phospholipid Vesicles

  • Alberto Gabizon
  • Dorit Goren
  • Avner Ramu
  • Yechezkel Barenholz
Part of the NATO ASI Series book series (NSSA, volume 113)


In this report we describe the design of adriamycin (ADM)-containing liposome preparations aiming at optimization of various pre-established parameters. Regarding liposome composition phosphatidylserine (PS) and phosphatidylglycerol (PG) appear to be suitable negatively charged phospholipids which combined with phosphatidylcholine (PC) and cholesterol (CHOL), confer to liposomes high loading capacity for ADM and reasonable stability in plasma. Intravenous administration of these negatively-charged liposomes resulted in a favorable tissue distribution of ADM in both normal and tumor-bearing mice, characterized by decreased cardiac uptake of drug, and increased and sustained drug levels in the liver. Moreover, enhanced accumulation of drug also occurred in metastatic tumor cells isolated from the liver when ADM was injected in the liposome-associated form. This passive drug targeting resulted in an improved therapeutic efficiency of liposome-associated ADM in a tumor model of liver metastases. Liposome delivery of ADM was also shown to increase significantly its cytoreductive effect on spleen-infiltrating leukemia cells and to maintain the same cytoreductive efficiency on bone marrow residing leukemia cells with an overall favorable effect on survival in the BCL1 leukemia model. The reduction of ADM toxicity by liposome association together with the anti-tumor results indicate that liposomes represent a useful drug-delivery system for the treatment of major neoplastic conditions.


Liposome Preparation Cardiac Uptake Tissue Distribution Study P388 Leukemia Cell Liposome Composition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Blum, R.H., Carter, S.K., and Agree, K., 1973, A clinical review of bleomycin: a new antineoplastic agent, Cancer, 31:903.CrossRefGoogle Scholar
  2. Forssen, E.A., and Tokes, Z.A., 1981, Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity, Proc. Natl. Acad. Sci. U.S.A., 78:1973.Google Scholar
  3. Gabizon, A., Dagan, A., Goren, D., Barenholz, Y., and Fuks, Z., 1982, Liposomes as in-vivo carriers of Adriamycin: reduced cardiac uptake and preserved anti-tumor activity in mice, Cancer Res., 42:4734.Google Scholar
  4. Gabizon, A., Goren, D., Fuks, Z., Barenholz, Y., Dagan, A., and Meshorer, A., 1983, Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers, Cancer Res., 43:4730.Google Scholar
  5. Gabizon, A., Goren, D., Fuks, Z., Meshorer, A., and Barenholz, Y., 1985, Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumor model, Br. J. Cancer, 51:681.Google Scholar
  6. Goormaghtigh, E. and Ruysschaert, J.M., 1984, Anthracycline glycoside membrane interactions, Biochim. Biophys. Acta, 779:271.Google Scholar
  7. Juliano, R.L. and Stamp, D., 1978, Pharmacokinetics of liposome-encapsulated anti-tumor drugs, Biochem. Pharmacol., 27:21.Google Scholar
  8. Kimeiberg, H.K., Tracy, T.F., Biddlecome, S.M., and Bourke, R.S., 1976, The effect of entrapment in liposomes on the in vivo distribution of 3H-methotrexate in a primate, Cancer Res., 36:2949.Google Scholar
  9. Mayhew, E. and Papahadjopoulos, D., 1983, Therapeutic applications of liposomes, in: “Liposomes,” M.J. Ostro, ed., Marcel Dekker, New York.Google Scholar
  10. Mayhew, E., Rustum, Y., and Vail, W.J., 1983, Inhibition of liver metastases of M5076 tumor by liposome-entrapped adriamycin, Cancer Drug. Deliv. 1:43.Google Scholar
  11. Minow, R.A., Benjamin, R.S., Gottlieb, J.A., 1975, Adriamycin (NSC-123127)-cardiomyopathy: an overview with determination of risk factors, Cancer Chemother. Rep., 6:195.Google Scholar
  12. Olson, F., Mayhew, E., Maslow, D., Rustum, Y., and Szoka, F., 1982, Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes, Eur. J. Cancer Clin. Oncol., 18:167.Google Scholar
  13. Poste, G., Bucana, C., Raz, A., Bugelski, P., Kirsh, R., and Fidler, I.J., 1982, Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery, Cancer Res., 42: 1412.Google Scholar
  14. Poste, G., 1983, Liposome targeting in vivo: problems and opportunities, Biol. Cell., 47:19.Google Scholar
  15. Rahman, Y., Wright, B.J., 1975, Liposomes containing chelating agents: Cellular penetration and a possible mechanism of metal removal, J. Cell. Biol., 65:112.Google Scholar
  16. Rahman, A., Kessler, A., More, N., Sikic, B., Rowden, G., Woolley, P., and Schein, P.S., 1980, Liposomal protection of adriamycin-induced cardiotoxicity in mice, Cancer Res., 40:1532.Google Scholar
  17. Rosenthal, S. and Kaufman, S., 1974, Vincristine neurotoxicity, Ann. Intern. Med., 80:733.Google Scholar
  18. Segal, A.W., Wills, E.J., Richmond, J.E., Slavin, G., Black, C.D.V., and Gregoriadis, G., 1974, Morphological observations on the cellular and subcellular destination of intravenously administered liposomes, Br. J. Exp. Pathol., 55:320.Google Scholar
  19. Van Hoesel, Q.G.C.M., Steerenberg, P.A., Crommelin, D.J.A., Van Dijk, A., Van Oort, W., Klein, S., Douze, J.M.C., deWildt, D.J., and Hillen, F.C., 1984, Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat, Cancer Res., 44:3698.Google Scholar
  20. Von Hoff, D.D., Layard, M.W., Basa, P., Davis, H.L., Von Hoff, A.L., Rozencweig, M., and Muggia, F.M., 1979, Risk factors for doxorubicin-induced congestive heart failure, Ann. Intern. Med., 91:710.Google Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Alberto Gabizon
    • 1
  • Dorit Goren
    • 1
  • Avner Ramu
    • 1
  • Yechezkel Barenholz
    • 2
  1. 1.Hadassah University HospitalJerusalemIsrael
  2. 2.Hebrew University-Hadassah Medical SchoolJerusalemIsrael

Personalised recommendations